Lexipafant

Drug Profile

Lexipafant

Alternative Names: BB 882; DO 6; GR 167089; Lexipafant - Vernalis; Zacutex

Latest Information Update: 02 Oct 2009

Price : $50

At a glance

  • Originator Vernalis
  • Developer DevCo Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antiplatelets; Branched-chain amino acids; Imidazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Platelet activating factor inhibitors; Platelet activating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cognition disorders; Neurological disorders; Pancreatitis; Reperfusion injury
  • Discontinued Arrhythmias; Asthma; Ischaemic heart disorders; Multiple sclerosis

Most Recent Events

  • 23 Mar 2004 Clinical data from a media release have been added to the pharmacokinetics section
  • 23 Mar 2004 Lexipafant is available for licensing (http://www.devcopharma.com)
  • 17 Mar 2004 Phase-II clinical trials in Reperfusion injury in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top